Clinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Clinical Trial to Investigate the Efficacy and Safety of WS016 in the Patients With Hyperkalemia
NCT06277128 is registered in ClinicalTrials.gov with Waterstone Pharmaceutical (Wuhan) Co., LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Clinical Trial to Investigate the Efficacy and Safety of WS016 in the Patients With Hyperkalemia
- Lead sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 11, 2023
- Completion date
- August 4, 2024
- Enrollment
- 140 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.